Last reviewed · How we verify
Optison echocardiography contrast agent
Optison echocardiography contrast agent is a Ultrasound contrast agent Small molecule drug developed by University of Utah. It is currently FDA-approved for Echocardiographic contrast enhancement for left ventricular opacification, Improvement of left ventricular border definition in patients with suboptimal echocardiograms. Also known as: Perflutren Protein-Type A microspheres.
Optison is a microbubble contrast agent that reflects ultrasound waves to enhance echocardiographic imaging of the heart.
Optison is a microbubble contrast agent that reflects ultrasound waves to enhance echocardiographic imaging of the heart. Used for Echocardiographic contrast enhancement for left ventricular opacification, Improvement of left ventricular border definition in patients with suboptimal echocardiograms.
At a glance
| Generic name | Optison echocardiography contrast agent |
|---|---|
| Also known as | Perflutren Protein-Type A microspheres |
| Sponsor | University of Utah |
| Drug class | Ultrasound contrast agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Optison consists of perfluorocarbon gas-filled microspheres stabilized by a human serum albumin shell. When injected intravenously, these microbubbles circulate through the bloodstream and reflect ultrasound energy, creating enhanced contrast in cardiac chambers and improving visualization of cardiac structures, wall motion, and perfusion during echocardiography.
Approved indications
- Echocardiographic contrast enhancement for left ventricular opacification
- Improvement of left ventricular border definition in patients with suboptimal echocardiograms
Common side effects
- Headache
- Nausea
- Chest pain or discomfort
- Flushing
- Hypersensitivity reactions
Key clinical trials
- Regadenoson Real Time Perfusion Imaging Trial-Optison (PHASE3)
- Study to Determine Safety and Dosage of OPTISON in Pediatric Participants (PHASE4)
- Pre-operative Evaluation of Kidney & Pancreas Transplant Patients (NA)
- Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection
- Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage (PHASE4)
- Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE) (PHASE1, PHASE2)
- Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI. (NA)
- A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optison echocardiography contrast agent CI brief — competitive landscape report
- Optison echocardiography contrast agent updates RSS · CI watch RSS
- University of Utah portfolio CI
Frequently asked questions about Optison echocardiography contrast agent
What is Optison echocardiography contrast agent?
How does Optison echocardiography contrast agent work?
What is Optison echocardiography contrast agent used for?
Who makes Optison echocardiography contrast agent?
Is Optison echocardiography contrast agent also known as anything else?
What drug class is Optison echocardiography contrast agent in?
What development phase is Optison echocardiography contrast agent in?
What are the side effects of Optison echocardiography contrast agent?
Related
- Drug class: All Ultrasound contrast agent drugs
- Manufacturer: University of Utah — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Echocardiographic contrast enhancement for left ventricular opacification
- Indication: Drugs for Improvement of left ventricular border definition in patients with suboptimal echocardiograms
- Also known as: Perflutren Protein-Type A microspheres
- Compare: Optison echocardiography contrast agent vs similar drugs
- Pricing: Optison echocardiography contrast agent cost, discount & access